तुलना करने के लिए मीट्रिक्स | SPRC | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधSPRCपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | 4.0x | 37.3x | −0.4x | |
PEG अनुपात | 0.01 | −0.16 | 0.00 | |
क़ीमत/बुक | 4.8x | 1.4x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 3.4x | 1.5x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 9.9% | 52.9% | |
उचित मूल्य अपसाइड | अनलॉक करें | 7.9% | 6.4% | अनलॉक करें |
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. In addition, it develops SCD-153 for the treatment of alopecia areata; and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.